Clorox

CLX · NYSE

$87.45+$1.89 (+2.21%)TodayMarket closed · Oct 20, 7:49 PM ET

Prev close $85.56

CLX analyst rating

HoldConsensus of 12 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold8
Underperform3
Sell1

12-month price target · 19 analysts

Average $102.53 (+17.2% upside)

Low: $77.77
Now: $87.45
High: $164.15

Upgrades and downgrades

The latest rating actions, newest first

CLX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 19, 2026	Maintains	Underweight	$95.00 → $83.00	58%
Barclays	Oct 16, 2026	Maintains	Underweight	$84.00 → $80.00	62%
Morgan Stanley	Oct 15, 2026	Maintains	Equal-Weight	$97.00 → $87.00	67%
Citigroup	Oct 14, 2026	Maintains	Neutral	$97.00 → $90.00	58%
TD Cowen	Oct 13, 2026	Maintains	Hold	$85.00 → $80.00	58%
Wells Fargo	Oct 5, 2026	Maintains	Equal-Weight	$90.00 → $85.00	57%
Citigroup	Sep 11, 2026	Maintains	Neutral	$100.00 → $97.00	58%
Wells Fargo	Sep 11, 2026	Maintains	Equal-Weight	$102.00 → $90.00	57%
UBS	Aug 4, 2026	Maintains	Neutral	$100.00 → $105.00	62%
JP Morgan	Aug 4, 2026	Maintains	Underweight	$92.00 → $95.00	58%

The case for and against

Updated Jul 18, 2025

Bull case

Clorox has demonstrated strong financial performance, exceeding internal expectations primarily due to robust sales growth in its Health & Wellness and International segments, with a notable 16.4% increase in consumption reported in recent sales data. The company's earnings per share also surpassed consensus estimates at $1.86, signaling solid profitability amid competitive pressures. Additionally, Clorox continues to improve market shares across most of its businesses for the second consecutive quarter and is positioned for growth through impactful innovation and recovery from recent cybersecurity challenges.

Bear case

Clorox faces a challenging operating environment, with management projecting minimal organic growth in the low single digits (+0-1%), primarily due to difficult comparisons from the previous year’s recovery following a cyberattack. The company is experiencing supply chain issues in specific categories such as bags and cat litter, which have resulted in slower performance recovery compared to other product lines. Additionally, Clorox is at risk from fluctuating input costs for raw materials and labor, and the highly competitive nature of the consumer products sector further complicates its ability to maintain profitability and sales levels.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.